DNDi-led Study Finds Safer, Shorter Treatment For Debilitating Chagas Disease 15/03/2019 Divya Schlesinger Severe side effects make the current course of prolonged drug treatment difficult for many patients with Chagas disease, but a Phase II clinical trial in Bolivia may have found an alternative treatment that is both quicker and significantly safer. Image Credits: Ana Ferreira/DNDi. Continue reading -> DRC Ebola Response: Need To “Find A Balance” Between Protecting Patients, Building Trust 14/03/2019 David Branigan World Health Organization Director-General Dr Tedros Adhanom Ghebreyesus told reporters today that WHO is “working to find a balance between protecting patients and staff from attacks by armed groups and building community trust and ownership” in managing the response to the deadly Ebola epidemic in the Democratic Republic of Congo. Image Credits: Gabriele François Casini/MSF. Continue reading -> WHA Resolution For Transparent Drug Pricing: Italy Speaks Out 12/03/2019 Elaine Ruth Fletcher Italy’s Minister of Health spoke out publicly today at a press conference in Rome on the proposed World Health Assembly resolution on drug price transparency, while an open letter published on the Ministry’s website called on other World Health Organization member states to support the initiative. Continue reading -> Short Regimen For TB Found To Be Safe With New First-Line HIV Drug 07/03/2019 William New In what is being called an "important moment" for tuberculosis (TB) control, a new study found that "a shorter regimen to prevent TB can be safely co-administered with dolutegravir (DTG)—the first-line drug to treat HIV in many high-burden TB countries," according to a release. Continue reading -> Strengthening Supply Chain Security For Essential Antimalarial Drugs 28/02/2019 David Branigan Secure and reliable supply chains for life-saving medicines are essential features of the global health landscape. They ensure that quality approved drugs are manufactured and available in the quantities needed, without interruption. For the fight against malaria, securing supply chains for quality, life-saving antimalarials involves the collective effort of a range of organisations working to mitigate the risk of any shortage of these drugs. A recent success in this area has been the quality approval of a second supplier of injectable artesunate, the drug recommended by the World Health Organization to treat severe malaria. Continue reading -> New Research Study Describes DNDi As “Commons” For Public Health 25/02/2019 David Branigan Since 2003, Drugs for Neglected Diseases Initiative (DNDi) has worked to meet the public health needs of neglected populations by filling gaps in drug development left by the for-profit pharmaceutical industry. A new research study by the French Development Agency analysed DNDi’s unique product development partnership (PDP) model, and found that it “illustrate[s] what can be presented as a ‘commons’ within the area of public health.” Continue reading -> Unitaid Calls For Proposals To Develop Technologies To Treat Malaria, HIV, TB 13/02/2019 David Branigan Unitaid has launched two separate calls for proposals for the development of improved technologies to better diagnose and treat Plasmodium vivax malaria, and to more effectively treat HIV and its coinfections, including tuberculosis and malaria, in low and middle-income countries. Continue reading -> Ending TB: Multi-Sectoral Collaboration Needed To Tackle Disease Of Poverty, Board Says 01/02/2019 Editorial team There is a need to strengthen multisectoral collaboration to halt the global tuberculosis epidemic, WHO Executive Board (EB) members said in a review of the WHO End TB Strategy, which aims to reduce TB deaths by 90 percent by 2030. Continue reading -> DNDi, MMV Make 400 Compounds Available To Boost Pandemic Disease Research 29/01/2019 William New The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) today announced the launch of the "Pandemic Response Box", which offers researchers free access to 400 compounds that could lead to development of new treatments for pandemic diseases. In return, researchers "will be expected to share data resulting from research on the molecules from the box in the public domain within 2 years of its generation." Continue reading -> G-Finder: R&D Investments Reach 10-Year Peak 23/01/2019 Health Policy Watch Funding for neglected disease research and development reached its highest level in a decade, with US $3.56 billion in investments in 2017. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
DRC Ebola Response: Need To “Find A Balance” Between Protecting Patients, Building Trust 14/03/2019 David Branigan World Health Organization Director-General Dr Tedros Adhanom Ghebreyesus told reporters today that WHO is “working to find a balance between protecting patients and staff from attacks by armed groups and building community trust and ownership” in managing the response to the deadly Ebola epidemic in the Democratic Republic of Congo. Image Credits: Gabriele François Casini/MSF. Continue reading -> WHA Resolution For Transparent Drug Pricing: Italy Speaks Out 12/03/2019 Elaine Ruth Fletcher Italy’s Minister of Health spoke out publicly today at a press conference in Rome on the proposed World Health Assembly resolution on drug price transparency, while an open letter published on the Ministry’s website called on other World Health Organization member states to support the initiative. Continue reading -> Short Regimen For TB Found To Be Safe With New First-Line HIV Drug 07/03/2019 William New In what is being called an "important moment" for tuberculosis (TB) control, a new study found that "a shorter regimen to prevent TB can be safely co-administered with dolutegravir (DTG)—the first-line drug to treat HIV in many high-burden TB countries," according to a release. Continue reading -> Strengthening Supply Chain Security For Essential Antimalarial Drugs 28/02/2019 David Branigan Secure and reliable supply chains for life-saving medicines are essential features of the global health landscape. They ensure that quality approved drugs are manufactured and available in the quantities needed, without interruption. For the fight against malaria, securing supply chains for quality, life-saving antimalarials involves the collective effort of a range of organisations working to mitigate the risk of any shortage of these drugs. A recent success in this area has been the quality approval of a second supplier of injectable artesunate, the drug recommended by the World Health Organization to treat severe malaria. Continue reading -> New Research Study Describes DNDi As “Commons” For Public Health 25/02/2019 David Branigan Since 2003, Drugs for Neglected Diseases Initiative (DNDi) has worked to meet the public health needs of neglected populations by filling gaps in drug development left by the for-profit pharmaceutical industry. A new research study by the French Development Agency analysed DNDi’s unique product development partnership (PDP) model, and found that it “illustrate[s] what can be presented as a ‘commons’ within the area of public health.” Continue reading -> Unitaid Calls For Proposals To Develop Technologies To Treat Malaria, HIV, TB 13/02/2019 David Branigan Unitaid has launched two separate calls for proposals for the development of improved technologies to better diagnose and treat Plasmodium vivax malaria, and to more effectively treat HIV and its coinfections, including tuberculosis and malaria, in low and middle-income countries. Continue reading -> Ending TB: Multi-Sectoral Collaboration Needed To Tackle Disease Of Poverty, Board Says 01/02/2019 Editorial team There is a need to strengthen multisectoral collaboration to halt the global tuberculosis epidemic, WHO Executive Board (EB) members said in a review of the WHO End TB Strategy, which aims to reduce TB deaths by 90 percent by 2030. Continue reading -> DNDi, MMV Make 400 Compounds Available To Boost Pandemic Disease Research 29/01/2019 William New The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) today announced the launch of the "Pandemic Response Box", which offers researchers free access to 400 compounds that could lead to development of new treatments for pandemic diseases. In return, researchers "will be expected to share data resulting from research on the molecules from the box in the public domain within 2 years of its generation." Continue reading -> G-Finder: R&D Investments Reach 10-Year Peak 23/01/2019 Health Policy Watch Funding for neglected disease research and development reached its highest level in a decade, with US $3.56 billion in investments in 2017. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
WHA Resolution For Transparent Drug Pricing: Italy Speaks Out 12/03/2019 Elaine Ruth Fletcher Italy’s Minister of Health spoke out publicly today at a press conference in Rome on the proposed World Health Assembly resolution on drug price transparency, while an open letter published on the Ministry’s website called on other World Health Organization member states to support the initiative. Continue reading -> Short Regimen For TB Found To Be Safe With New First-Line HIV Drug 07/03/2019 William New In what is being called an "important moment" for tuberculosis (TB) control, a new study found that "a shorter regimen to prevent TB can be safely co-administered with dolutegravir (DTG)—the first-line drug to treat HIV in many high-burden TB countries," according to a release. Continue reading -> Strengthening Supply Chain Security For Essential Antimalarial Drugs 28/02/2019 David Branigan Secure and reliable supply chains for life-saving medicines are essential features of the global health landscape. They ensure that quality approved drugs are manufactured and available in the quantities needed, without interruption. For the fight against malaria, securing supply chains for quality, life-saving antimalarials involves the collective effort of a range of organisations working to mitigate the risk of any shortage of these drugs. A recent success in this area has been the quality approval of a second supplier of injectable artesunate, the drug recommended by the World Health Organization to treat severe malaria. Continue reading -> New Research Study Describes DNDi As “Commons” For Public Health 25/02/2019 David Branigan Since 2003, Drugs for Neglected Diseases Initiative (DNDi) has worked to meet the public health needs of neglected populations by filling gaps in drug development left by the for-profit pharmaceutical industry. A new research study by the French Development Agency analysed DNDi’s unique product development partnership (PDP) model, and found that it “illustrate[s] what can be presented as a ‘commons’ within the area of public health.” Continue reading -> Unitaid Calls For Proposals To Develop Technologies To Treat Malaria, HIV, TB 13/02/2019 David Branigan Unitaid has launched two separate calls for proposals for the development of improved technologies to better diagnose and treat Plasmodium vivax malaria, and to more effectively treat HIV and its coinfections, including tuberculosis and malaria, in low and middle-income countries. Continue reading -> Ending TB: Multi-Sectoral Collaboration Needed To Tackle Disease Of Poverty, Board Says 01/02/2019 Editorial team There is a need to strengthen multisectoral collaboration to halt the global tuberculosis epidemic, WHO Executive Board (EB) members said in a review of the WHO End TB Strategy, which aims to reduce TB deaths by 90 percent by 2030. Continue reading -> DNDi, MMV Make 400 Compounds Available To Boost Pandemic Disease Research 29/01/2019 William New The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) today announced the launch of the "Pandemic Response Box", which offers researchers free access to 400 compounds that could lead to development of new treatments for pandemic diseases. In return, researchers "will be expected to share data resulting from research on the molecules from the box in the public domain within 2 years of its generation." Continue reading -> G-Finder: R&D Investments Reach 10-Year Peak 23/01/2019 Health Policy Watch Funding for neglected disease research and development reached its highest level in a decade, with US $3.56 billion in investments in 2017. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Short Regimen For TB Found To Be Safe With New First-Line HIV Drug 07/03/2019 William New In what is being called an "important moment" for tuberculosis (TB) control, a new study found that "a shorter regimen to prevent TB can be safely co-administered with dolutegravir (DTG)—the first-line drug to treat HIV in many high-burden TB countries," according to a release. Continue reading -> Strengthening Supply Chain Security For Essential Antimalarial Drugs 28/02/2019 David Branigan Secure and reliable supply chains for life-saving medicines are essential features of the global health landscape. They ensure that quality approved drugs are manufactured and available in the quantities needed, without interruption. For the fight against malaria, securing supply chains for quality, life-saving antimalarials involves the collective effort of a range of organisations working to mitigate the risk of any shortage of these drugs. A recent success in this area has been the quality approval of a second supplier of injectable artesunate, the drug recommended by the World Health Organization to treat severe malaria. Continue reading -> New Research Study Describes DNDi As “Commons” For Public Health 25/02/2019 David Branigan Since 2003, Drugs for Neglected Diseases Initiative (DNDi) has worked to meet the public health needs of neglected populations by filling gaps in drug development left by the for-profit pharmaceutical industry. A new research study by the French Development Agency analysed DNDi’s unique product development partnership (PDP) model, and found that it “illustrate[s] what can be presented as a ‘commons’ within the area of public health.” Continue reading -> Unitaid Calls For Proposals To Develop Technologies To Treat Malaria, HIV, TB 13/02/2019 David Branigan Unitaid has launched two separate calls for proposals for the development of improved technologies to better diagnose and treat Plasmodium vivax malaria, and to more effectively treat HIV and its coinfections, including tuberculosis and malaria, in low and middle-income countries. Continue reading -> Ending TB: Multi-Sectoral Collaboration Needed To Tackle Disease Of Poverty, Board Says 01/02/2019 Editorial team There is a need to strengthen multisectoral collaboration to halt the global tuberculosis epidemic, WHO Executive Board (EB) members said in a review of the WHO End TB Strategy, which aims to reduce TB deaths by 90 percent by 2030. Continue reading -> DNDi, MMV Make 400 Compounds Available To Boost Pandemic Disease Research 29/01/2019 William New The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) today announced the launch of the "Pandemic Response Box", which offers researchers free access to 400 compounds that could lead to development of new treatments for pandemic diseases. In return, researchers "will be expected to share data resulting from research on the molecules from the box in the public domain within 2 years of its generation." Continue reading -> G-Finder: R&D Investments Reach 10-Year Peak 23/01/2019 Health Policy Watch Funding for neglected disease research and development reached its highest level in a decade, with US $3.56 billion in investments in 2017. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Strengthening Supply Chain Security For Essential Antimalarial Drugs 28/02/2019 David Branigan Secure and reliable supply chains for life-saving medicines are essential features of the global health landscape. They ensure that quality approved drugs are manufactured and available in the quantities needed, without interruption. For the fight against malaria, securing supply chains for quality, life-saving antimalarials involves the collective effort of a range of organisations working to mitigate the risk of any shortage of these drugs. A recent success in this area has been the quality approval of a second supplier of injectable artesunate, the drug recommended by the World Health Organization to treat severe malaria. Continue reading -> New Research Study Describes DNDi As “Commons” For Public Health 25/02/2019 David Branigan Since 2003, Drugs for Neglected Diseases Initiative (DNDi) has worked to meet the public health needs of neglected populations by filling gaps in drug development left by the for-profit pharmaceutical industry. A new research study by the French Development Agency analysed DNDi’s unique product development partnership (PDP) model, and found that it “illustrate[s] what can be presented as a ‘commons’ within the area of public health.” Continue reading -> Unitaid Calls For Proposals To Develop Technologies To Treat Malaria, HIV, TB 13/02/2019 David Branigan Unitaid has launched two separate calls for proposals for the development of improved technologies to better diagnose and treat Plasmodium vivax malaria, and to more effectively treat HIV and its coinfections, including tuberculosis and malaria, in low and middle-income countries. Continue reading -> Ending TB: Multi-Sectoral Collaboration Needed To Tackle Disease Of Poverty, Board Says 01/02/2019 Editorial team There is a need to strengthen multisectoral collaboration to halt the global tuberculosis epidemic, WHO Executive Board (EB) members said in a review of the WHO End TB Strategy, which aims to reduce TB deaths by 90 percent by 2030. Continue reading -> DNDi, MMV Make 400 Compounds Available To Boost Pandemic Disease Research 29/01/2019 William New The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) today announced the launch of the "Pandemic Response Box", which offers researchers free access to 400 compounds that could lead to development of new treatments for pandemic diseases. In return, researchers "will be expected to share data resulting from research on the molecules from the box in the public domain within 2 years of its generation." Continue reading -> G-Finder: R&D Investments Reach 10-Year Peak 23/01/2019 Health Policy Watch Funding for neglected disease research and development reached its highest level in a decade, with US $3.56 billion in investments in 2017. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
New Research Study Describes DNDi As “Commons” For Public Health 25/02/2019 David Branigan Since 2003, Drugs for Neglected Diseases Initiative (DNDi) has worked to meet the public health needs of neglected populations by filling gaps in drug development left by the for-profit pharmaceutical industry. A new research study by the French Development Agency analysed DNDi’s unique product development partnership (PDP) model, and found that it “illustrate[s] what can be presented as a ‘commons’ within the area of public health.” Continue reading -> Unitaid Calls For Proposals To Develop Technologies To Treat Malaria, HIV, TB 13/02/2019 David Branigan Unitaid has launched two separate calls for proposals for the development of improved technologies to better diagnose and treat Plasmodium vivax malaria, and to more effectively treat HIV and its coinfections, including tuberculosis and malaria, in low and middle-income countries. Continue reading -> Ending TB: Multi-Sectoral Collaboration Needed To Tackle Disease Of Poverty, Board Says 01/02/2019 Editorial team There is a need to strengthen multisectoral collaboration to halt the global tuberculosis epidemic, WHO Executive Board (EB) members said in a review of the WHO End TB Strategy, which aims to reduce TB deaths by 90 percent by 2030. Continue reading -> DNDi, MMV Make 400 Compounds Available To Boost Pandemic Disease Research 29/01/2019 William New The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) today announced the launch of the "Pandemic Response Box", which offers researchers free access to 400 compounds that could lead to development of new treatments for pandemic diseases. In return, researchers "will be expected to share data resulting from research on the molecules from the box in the public domain within 2 years of its generation." Continue reading -> G-Finder: R&D Investments Reach 10-Year Peak 23/01/2019 Health Policy Watch Funding for neglected disease research and development reached its highest level in a decade, with US $3.56 billion in investments in 2017. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Unitaid Calls For Proposals To Develop Technologies To Treat Malaria, HIV, TB 13/02/2019 David Branigan Unitaid has launched two separate calls for proposals for the development of improved technologies to better diagnose and treat Plasmodium vivax malaria, and to more effectively treat HIV and its coinfections, including tuberculosis and malaria, in low and middle-income countries. Continue reading -> Ending TB: Multi-Sectoral Collaboration Needed To Tackle Disease Of Poverty, Board Says 01/02/2019 Editorial team There is a need to strengthen multisectoral collaboration to halt the global tuberculosis epidemic, WHO Executive Board (EB) members said in a review of the WHO End TB Strategy, which aims to reduce TB deaths by 90 percent by 2030. Continue reading -> DNDi, MMV Make 400 Compounds Available To Boost Pandemic Disease Research 29/01/2019 William New The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) today announced the launch of the "Pandemic Response Box", which offers researchers free access to 400 compounds that could lead to development of new treatments for pandemic diseases. In return, researchers "will be expected to share data resulting from research on the molecules from the box in the public domain within 2 years of its generation." Continue reading -> G-Finder: R&D Investments Reach 10-Year Peak 23/01/2019 Health Policy Watch Funding for neglected disease research and development reached its highest level in a decade, with US $3.56 billion in investments in 2017. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Ending TB: Multi-Sectoral Collaboration Needed To Tackle Disease Of Poverty, Board Says 01/02/2019 Editorial team There is a need to strengthen multisectoral collaboration to halt the global tuberculosis epidemic, WHO Executive Board (EB) members said in a review of the WHO End TB Strategy, which aims to reduce TB deaths by 90 percent by 2030. Continue reading -> DNDi, MMV Make 400 Compounds Available To Boost Pandemic Disease Research 29/01/2019 William New The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) today announced the launch of the "Pandemic Response Box", which offers researchers free access to 400 compounds that could lead to development of new treatments for pandemic diseases. In return, researchers "will be expected to share data resulting from research on the molecules from the box in the public domain within 2 years of its generation." Continue reading -> G-Finder: R&D Investments Reach 10-Year Peak 23/01/2019 Health Policy Watch Funding for neglected disease research and development reached its highest level in a decade, with US $3.56 billion in investments in 2017. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
DNDi, MMV Make 400 Compounds Available To Boost Pandemic Disease Research 29/01/2019 William New The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) today announced the launch of the "Pandemic Response Box", which offers researchers free access to 400 compounds that could lead to development of new treatments for pandemic diseases. In return, researchers "will be expected to share data resulting from research on the molecules from the box in the public domain within 2 years of its generation." Continue reading -> G-Finder: R&D Investments Reach 10-Year Peak 23/01/2019 Health Policy Watch Funding for neglected disease research and development reached its highest level in a decade, with US $3.56 billion in investments in 2017. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
G-Finder: R&D Investments Reach 10-Year Peak 23/01/2019 Health Policy Watch Funding for neglected disease research and development reached its highest level in a decade, with US $3.56 billion in investments in 2017. Continue reading -> Posts navigation Older postsNewer posts